Cytokinetics, Inc. (NASDAQ:CYTK) CEO Robert I. Blum sold 6,000 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $12.64, for a total value of $75,840.00. Following the completion of the transaction, the chief executive officer now owns 250,022 shares of the company’s stock, valued at $3,160,278.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
NASDAQ:CYTK traded up $0.77 on Friday, hitting $13.26. 444,400 shares of the stock were exchanged, compared to its average volume of 537,139. The stock has a market cap of $741.11 million, a PE ratio of -6.80 and a beta of 1.66. The company has a current ratio of 8.42, a quick ratio of 7.09 and a debt-to-equity ratio of 12.35. The stock has a fifty day moving average of $11.88 and a 200-day moving average of $9.55. Cytokinetics, Inc. has a fifty-two week low of $5.75 and a fifty-two week high of $14.25.
Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.06). Cytokinetics had a negative return on equity of 575.21% and a negative net margin of 308.73%. The company had revenue of $7.14 million during the quarter, compared to analysts’ expectations of $6.81 million. As a group, analysts predict that Cytokinetics, Inc. will post -2 earnings per share for the current year.
Several equities analysts recently commented on the company. Zacks Investment Research lowered Cytokinetics from a “hold” rating to a “sell” rating in a research note on Tuesday. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 target price on shares of Cytokinetics in a research note on Friday, May 10th. HC Wainwright upped their target price on Cytokinetics from $21.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, May 6th. Morgan Stanley set a $16.00 price target on Cytokinetics and gave the stock a “hold” rating in a research note on Friday, August 9th. Finally, BidaskClub lowered Cytokinetics from a “strong-buy” rating to a “buy” rating in a research note on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Cytokinetics presently has an average rating of “Buy” and a consensus price target of $16.00.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Featured Story: What does an inverted yield curve signify?
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.